Evidence for ApoE receptor 2-Disabled homolog-1 pathway disruption in the amygdala in sporadic Alzheimer's disease

INTRODUCTIONThe ApoE receptor 2-Disabled homolog-1 (ApoER2-Dab1) pathway suppresses Tau phosphorylation as part of a multi-arm pathway that regulates cytoskeletal and synaptic integrity. We previously showed that multiple ApoER2-Dab1 pathway components accumulate in regions affected in early Alzheimers disease (AD). Since the amygdala is a hub for emotional regulation and fear memory, we hypothesized that accumulation of ApoER2-Dab1 components in amygdala may correlate with cognitive or neuropsychiatric manifestations of AD. METHODSWe used single-marker and multiplex immunohistochemistry to label ApoER2-Dab1 components in amygdala from 32 cases spanning the clinicopathological spectrum of AD. RESULTSSeven ApoER2-Dab1 pathway components accumulated in amygdala and correlated with histological progression and cognitive or neurobehavioral deficits in AD. ApoER2-Dab1 components accumulated within ApoER2-expressing neurons and dystrophic neurites surrounding ApoE-enriched extracellular plaques. DISCUSSIONFindings add to growing evidence implicating ApoER2-Dab1 disruption in neurodegeneration and suggest that ApoER2-Dab1 disruption in amygdala may contribute to neuropsychiatric manifestations of AD.